Key Points – ORLADEYO revenue rose 10% year over year to $158.2 million in Q2, while pediatric oral-pellet shipments began with 47 prescriptions by July 31.
BioCryst maintained its 2026 ORLADEYO revenue outlook of $625 million to $645 million. – BioCryst completed enrollment in the pivotal ALPHA-ORBIT trial of long-acting injectable navenibart for hereditary angioedema, with top-line results expected in Q3 2027
Its BCX17725 study for Netherton syndrome is also enrolling and remains on track for early data by the end of 2026. – The company reduced 2026 non-GAAP operating-cost guidance to $420 million-$440 million after deciding to end internal drug discovery and close its Birmingham research facility by the end of 2026. BioCryst ended the quarter with more than $350 million in cash, equivalents and investments and plans to focus future innovation efforts on external partnerships. BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE.
President and CEO Charlie Gayer said the company completed the integration of Astria Therapeutics during the quarter and increased cash generation through revenue growth and spending discipline. BioCryst also decided in June to discontinue its internal drug-discovery programs and close its Birmingham research facility by the end of 2026, shifting its research strategy toward externally sourced innovation. ORLADEYO Revenue and Pediatric Launch ORLADEYO revenue totaled $158.2 million in the second quarter, rising 10% from a year earlier on a comparable basis that excludes BioCryst’s divested European business, Chief Financial Officer Babar Ghias said.